Union Therapeutics presents topline results for psoriasis drug
The biotech company announces positive data from a phase II trial of orismilast, a treatment candidate for moderate-to-severe psoriasis.
by albert rønning-andersson, translated by daniel pedersen
Union Therapeutics, a privately owned Danish biotech company, is one step closer to entering the treatment market for patients with psoriases.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Union Therapeutics begins phase IIb trial of eczema tablet
For subscribers
